Takeda Pharmaceutical Company Limited (TAK), Thursday announced the U.S. availability of GAMMAGARD LIQUID ERC, which is approved as a replacement therapy for people two years of age and older with primary immunodeficiency.
GAMMAGARD LIQUID ERC is a ready-to-use liquid immunoglobulin therapy with an IgA content of less than or equal to 2 µg/mL in a 10 percent solution to be administered intravenously or subcutaneously.
"As the latest addition to our broad IG portfolio, GAMMAGARD LIQUID ERC underscores our ongoing dedication to providing differentiated therapeutic options to meet the varied needs of people with primary immunodeficiency, including those who require an option with low IgA content," said Uthra Sundaram, senior vice president and head of Takeda's U.S. Plasma-Derived Therapies Business Unit.
In the pre-market hours, TAK is trading at $15.97, down 0.73 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.